NRx Pharmaceuticals has begun its first commercial manufacturing order for its preservative‑free ketamine product, a key step toward the anticipated summer 2026 launch of KETAFREE. The new production line uses a blow‑fill‑seal process that delivers more than ten times the throughput of traditional sterile bottling methods, and the order is supported by stability data from more than three manufactured registration batches and a third‑party audit of the facility.
Glenn Tyson has been named Chief Commercial Officer, and NRx is building a full commercial team to support the product’s rollout. Tyson’s appointment, announced on April 13 2026, signals the company’s intent to accelerate market entry and scale production rapidly as demand grows.
The move addresses ongoing supply shortages in the sterile ketamine market, where hand‑cleaner and antiseptic regulations have limited the availability of preservative‑free formulations. By establishing a domestic manufacturing base and offering a benzethonium chloride‑free product—benzethonium chloride is now banned from new drugs—NRx positions KETAFREE as the safest option in a market that currently has a $750 million generic ketamine opportunity worldwide.
NRx’s strategy to capture a share of this market is supported by regulatory milestones: a preliminary determination of bioequivalence, preliminary alignment on labeling, and a citizen petition to remove benzethonium chloride from ketamine products. The company’s ANDA goal date is July 29 2026, and the commercial launch is slated for summer 2026.
Financially, NRx has operated at a net loss of $5.5 million in Q1 2025 versus $6.5 million in Q1 2024, with current revenue of $242 k in Q3 2025. The commercial manufacturing capacity is expected to generate substantial annual revenues once FDA approval is obtained, providing a critical revenue stream for a company that has been investing heavily in its neuroplasticity pipeline, including NRX‑101, an oral therapeutic for suicidal bipolar depression that has received Breakthrough Therapy Designation.
"We hope to alleviate the supply shortages that have frequently been reported in association with sterile ketamine," said Dr. Jonathan Javitt, Chairman and CEO of NRx Pharmaceuticals.
The announcement underscores NRx’s commitment to addressing a pressing market need while positioning itself for long‑term growth in the expanding global ketamine market, projected to reach $6.1 billion by 2033.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.